Friedemann Paul, MD, Charité-Universitätsmedizin Berlin, Berlin, Germany, describes the findings from an analysis evaluating long-term outcomes of inebilizumab treatment in AQP4+ NMOSD participants from the N-MOmentum trial (NCT02200770) with a history of immunosuppressant therapy as compared to those without. N-Momentum was a 28-week-randomized Phase II/III trial of inebilizumab vs. placebo, with an optional open-label extension. In the analysis, AQP4+ participants who received inebilizumab were grouped by no history of immunosuppression therapy beyond the treatment of acute NMOSD attacks (naïve) or prior azathioprine (AZA) and/or mycophenolate mofetil (MMF) therapy. Results showed that AQP4+ NMOSD participants treated with prior AZA/MMF therapy demonstrated a similar efficacy and safety profile as participants without prior immunosuppressant therapy. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Grants or contracts: German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Einstein Foundation, Guthy Jackson Charitable Foundation, EU FP7 Framework Program, Biogen, Genzyme, Merck Serono, Novartis, Bayer, Roche, Parexel and Almirall.
Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Guthy Jackson Foundation, Bayer, Biogen, Merck Serono, Sanofi Genzyme, Novartis, Alexion, Viela Bio, Roche, UCB, Mitsubishi Tanabe and Celgene.
Participation on a Data Safety Monitoring Board or Advisory Board: Celgene, Roche, UCB, Merck.
Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Academic Editor PLos One, Associate Editor von Neurology® Neuroimmunology & Neuroinflammation.